RAPT Therapeutics, Inc. (NASDAQ:RAPT) saw a significant increase in short interest in the month of April. As of April 15th, there was short interest totalling 1,160,000 shares, an increase of 27.6% from the March 31st total of 908,900 shares. Based on an average trading volume of 143,400 shares, the days-to-cover ratio is presently 8.1 days. Currently, 7.2% of the shares of the company are sold short.
Shares of RAPT traded down $0.13 during midday trading on Tuesday, hitting $21.91. 91,223 shares of the stock traded hands, compared to its average volume of 146,785. RAPT Therapeutics has a 1-year low of $14.09 and a 1-year high of $41.86. The business’s 50 day moving average price is $21.89 and its two-hundred day moving average price is $22.73. The firm has a market capitalization of $544.86 million, a PE ratio of -8.63 and a beta of -0.03.
RAPT Therapeutics (NASDAQ:RAPT) last issued its quarterly earnings data on Thursday, March 11th. The company reported ($0.52) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.06. The company had revenue of $1.30 million for the quarter, compared to the consensus estimate of $2.05 million. As a group, equities analysts forecast that RAPT Therapeutics will post -2.18 earnings per share for the current fiscal year.
Separately, HC Wainwright boosted their price target on shares of RAPT Therapeutics from $30.00 to $32.00 and gave the company a “buy” rating in a report on Thursday, March 18th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. RAPT Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $38.40.
About RAPT Therapeutics
RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead oncology drug candidate is FLX475, an oral small molecule C-C motif chemokine receptor 4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer.
Read More: Moving Average (MA)
Receive News & Ratings for RAPT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RAPT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.